QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
NASDAQ:EKSO

Ekso Bionics (EKSO) Stock Forecast, Price & News

$0.69
-0.02 (-2.83%)
(As of 09/21/2023 ET)
Compare
Today's Range
$0.65
$0.77
50-Day Range
$0.69
$1.38
52-Week Range
$0.62
$1.91
Volume
31,573 shs
Average Volume
37,198 shs
Market Capitalization
$9.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Ekso Bionics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,211.8% Upside
$9.00 Price Target
Short Interest
Healthy
0.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.33mentions of Ekso Bionics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$50,230 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.29) to ($0.87) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars


EKSO stock logo

About Ekso Bionics (NASDAQ:EKSO) Stock

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therap, an adjustable and lower-limb powered exoskeleton; and Ekso Indego Personal, a powered lower limb orthosis. It has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in San Rafael, California.

EKSO Price History

EKSO Stock News Headlines

StockNews.com Initiates Coverage on Ekso Bionics (NASDAQ:EKSO)
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Short Interest Update
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Q2 2023 Ekso Bionics Holdings Inc Earnings Call
EKSO - Ekso Bionics Holdings, Inc.
See More Headlines
Receive EKSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ekso Bionics and its competitors with MarketBeat's FREE daily newsletter.

EKSO Company Calendar

Last Earnings
7/27/2023
Today
9/21/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
General industrial machinery,
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EKSO
Previous Symbol
OTCMKTS:EKSOD
Employees
72
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+1,211.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-15,080,000.00
Net Margins
-102.52%
Pretax Margin
-102.52%

Debt

Sales & Book Value

Annual Sales
$12.91 million
Book Value
$1.94 per share

Miscellaneous

Free Float
12,771,000
Market Cap
$9.48 million
Optionable
Not Optionable
Beta
1.75
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Scott G. Davis (Age 53)
    CEO & Director
    Comp: $535.8k
  • Mr. Jerome Wong (Age 49)
    Corp. Controller, Corp. Sec. & CFO
    Comp: $356.81k
  • Mr. Jason C. Jones
    Chief Operating Officer
  • Ms. Rachael Anderson
    Global Director of Marketing & Strategic Growth
  • Mr. Anthony Pratt
    VP of Sales
  • Ms. Ann Cookson
    HR Director
  • Ms. Foon Lim Chwee
    Pres of APAC
  • Mr. Stephan Aderhold
    Sr. VP & GM of EMEA













EKSO Stock - Frequently Asked Questions

Should I buy or sell Ekso Bionics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" EKSO shares.
View EKSO analyst ratings
or view top-rated stocks.

What is Ekso Bionics' stock price forecast for 2023?

1 brokers have issued 12-month price targets for Ekso Bionics' shares. Their EKSO share price forecasts range from $9.00 to $9.00. On average, they expect the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 1,211.8% from the stock's current price.
View analysts price targets for EKSO
or view top-rated stocks among Wall Street analysts.

How have EKSO shares performed in 2023?

Ekso Bionics' stock was trading at $1.19 at the beginning of 2023. Since then, EKSO shares have decreased by 42.3% and is now trading at $0.6861.
View the best growth stocks for 2023 here
.

Are investors shorting Ekso Bionics?

Ekso Bionics saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 36,100 shares, an increase of 32.7% from the August 15th total of 27,200 shares. Based on an average daily volume of 51,700 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.3% of the shares of the company are sold short.
View Ekso Bionics' Short Interest
.

When is Ekso Bionics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our EKSO earnings forecast
.

How were Ekso Bionics' earnings last quarter?

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) released its quarterly earnings data on Thursday, July, 27th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.03. The business had revenue of $4.70 million for the quarter, compared to analyst estimates of $4.35 million. Ekso Bionics had a negative net margin of 102.52% and a negative trailing twelve-month return on equity of 69.14%.

When did Ekso Bionics' stock split?

Ekso Bionics's stock reverse split on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 4th 2016. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of Ekso Bionics own?
What is Ekso Bionics' stock symbol?

Ekso Bionics trades on the NASDAQ under the ticker symbol "EKSO."

Who are Ekso Bionics' major shareholders?

Ekso Bionics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Citadel Advisors LLC (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Jason C Jones, Jerome Wong, John Glenn, Scott G Davis and Steven Sherman.
View institutional ownership trends
.

How do I buy shares of Ekso Bionics?

Shares of EKSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ekso Bionics' stock price today?

One share of EKSO stock can currently be purchased for approximately $0.69.

How much money does Ekso Bionics make?

Ekso Bionics (NASDAQ:EKSO) has a market capitalization of $9.48 million and generates $12.91 million in revenue each year. The company earns $-15,080,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis.

How can I contact Ekso Bionics?

Ekso Bionics' mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The official website for the company is www.eksobionics.com. The company can be reached via phone at (510) 984-1761, via email at investors@eksobionics.com, or via fax at 510-927-2647.

This page (NASDAQ:EKSO) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -